Dear Friend of LLS,
We've talked before about the kind of impact LLS is having on finding more effective treatments and cures for blood cancers. Some of you have personally felt the advances that our research is delivering. But like everything else it's a wonderful validation to be able to get positive feedback from authorities in the field.
In the July issue of Runners World (http://community.lls.org/blogs/tnt/2011/06/07/awash-in-purple-the-runners-world-july-issue) we get just that! There is a powerful segment dedicated to "outrunning cancer", the differences we can make by running for the cause and inspiring stories highlighting survivors.
In this article Team In Training is mentioned frequently. In fact it points out TNT has raised more than 1 billion dollars since 1988. What's most exciting is the mention of our funding of research that led to the development of the breakthrough cancer drug Gleevec. First approved to treat patients with chronic myelogenous leukemia, it's now being tested for patients with breast, ovarian and prostate cancer as well as nerve, brain and small cell lung cancers. And Gleevec is also being tested on melanoma and other diseases.
There is even a feature on Dr. Brian Druker. He developed Gleevec with funding in part by TNT! Here's what he had to say about us:
"The Leukemia & Lymphoma Society recognized the opportunity with Gleevec," Dr. Drucker says. "They were willing to take a chance on our work. Unfortunately, researchers today are basically in the same position as we were a decade ago. If anything, it's even more difficult for novel research to gain federal funding.
We're more reliant than ever on private non-profits like LLS."
Dr. Brian Drucker
I'm sure you'll enjoy the TNT coverage in Runners World and hope that you'll be as excited about this great "press" as we are.
Your support always makes an impact. Thank you.
Wishing you the best of health,
John E. Walter
President & CEO